# Phase 1 Safety and Tolerability Study of Andes-1537 for Injection in Patients With Advanced Unresectable Solid Tumors

> **NCT02508441** · PHASE1 · TERMINATED · sponsor: **Andes Biotechnologies** · enrollment: 22 (actual)

## Conditions studied

- Advanced Unresectable Solid Tumors

## Interventions

- **DRUG:** Andes-1537 for Injection

## Key facts

- **NCT ID:** NCT02508441
- **Lead sponsor:** Andes Biotechnologies
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-12-08
- **Primary completion:** 2017-11-13
- **Final completion:** 2017-11-13
- **Target enrollment:** 22 (ACTUAL)
- **Why stopped:** Part 1 of the study was completed and the maximum tolerated dose determined. Part 2 of the study was terminated and will be conducted under a new protocol.
- **Last updated:** 2018-10-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02508441

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02508441, "Phase 1 Safety and Tolerability Study of Andes-1537 for Injection in Patients With Advanced Unresectable Solid Tumors". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02508441. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*